CONFERENCE DAY TWO: May 23, 2024
8:15 am Check-In, Coffee & Light Breakfast
8:50 am Chair’s Opening Remarks
Leveraging Degraders as ADC Payloads: Balancing Safety & Efficacy
9:00 am Exploring the PROxAb Shuttle: A Plug & Play Solution for Targeted Antibody-Mediated PROTAC Delivery
Synopsis
- Displaying how targeting delivery of PROTACs via antibodies improves both safety and PK profiles
- Leveraging the PROxAb Shuttle as a Plug&Play technology that enables targeted delivery of PROTACs without any PROTAC modification
- Validating PROxAb Shuttles in-vivo and generating within only a few weeks
9:30 am Uncovering Protein Homeostasis by Dual Precision Approach & Development of a Novel Catalytic Payload Class With an Improved Safety and Efficacy Profile & Exploring Diversity of degrader SAR
Synopsis
- Development of a novel, catalytic payload class leveraging catalytic enzmes to disrupt cellular processes
- Exploring the diversity of degrader SAR studies while also enabling conjugation to targeting format
- Improving potency and selectivity of delivery to target cells with catalytic action allowing for lower payload doses
10:00 am Morning Coffee & Refreshments Break
Exploring Novel Approaches for Anti-Tumor Treatment via ADC Payload Mechanism of Action & Dual Payload Approaches
11:00 am Roundtable Discussion – Exploring Potential of ADC Payloads: Small Molecule Cytotoxins, DNA Damaging Agents, PROTACS & Oligonucleotides
Synopsis
- Discussing payload delivery through TM4SF1-guided new internalization mechanism of action
- Uncovering the potential ADC payloads: small molecule cytotoxins or DNA damaging agents, PROTACs (degrader), and oligonucleotides (ASO or siRNA)
- Leveraging tumor endothelium targeting to improve ADC payload efficacy
11:30 am Session Reserved for Abzena
Synopsis
11:45 am Targeting KIF20A Kinesin: A Promising Strategy for Next-Generation ADC Payload
Synopsis
- Presenting EVX-020, a first-in-class highly selective KIF20A inhibitor
- Sharing nonclinical efficacy data of EVX-020 in tumor models and the involvement of KIF20A in Golgi Function
- Analyzing the MoA of EVX-020, and its potential as a new ADC payload
12:15 pm Lunch
Further Progressing TOPI Inhibitor Payloads to Improve Tumor Specificity & Leveraging SARs to Optimize Payloads
1:15 pm Expanding Selection of Tubulin & TOPI Inhibitor Payloads for Improved Tumor Specific Delivery by Peptide Drug Conjugate
Synopsis
- Considering the stability of linker-warhead peptide conjugates when working with TOPI inhibitor and tubulin inhibitors
- Improving tumor specificity of warhead delivery for improved therapeutic window
- Describing preclinical efficacy and safety profile, both clinical and non-clinical for Auristatin and Topo1 assets
Navigating Current ADC Payload Trends & Predicting the Future of the ADC Payload Field
1:45 pm
Panel: Considering Future Clinical Applicability of Novel Payloads Currently in Discovery
Chairs:
Synopsis
- Thinking about the future of the clinical landscape in comparison to now, and what the most promising novel payload contenders are
- Realizing feasibility of some novel payloads: thinking about developmental or future safety concerns with novel mechanisms of action
- Identifying gaps for development of novel payloads from the current landscape